|
|
|
| 局部进展期前列腺癌综合诊疗1例并文献复习 |
| 路义, 王鹏, 赵海军, 邓军, 张晏, 吴帅, 祝海* |
| 青岛大学医学院附属青岛市市立医院泌尿外科,青岛 266000 |
|
| Comprehensive diagnosis and treatment of locally advanced prostate cancer: one case report and literature review |
| Lu Yi, Wang Peng, Zhao Haijun, Deng Jun, Zhang Yan, Wu Shuai, Zhu Hai* |
| Department of Urology, Qingdao Municipal Hospital, affiliated to Qingdao University Medical College, Qingdao 266000 |
| 引用本文: |
路义, 王鹏, 赵海军, 邓军, 张晏, 吴帅, 祝海. 局部进展期前列腺癌综合诊疗1例并文献复习[J]. 微创泌尿外科杂志, 2022, 11(2): 128-130.
Lu Yi, Wang Peng, Zhao Haijun, Deng Jun, Zhang Yan, Wu Shuai, Zhu Hai. Comprehensive diagnosis and treatment of locally advanced prostate cancer: one case report and literature review. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2022, 11(2): 128-130.
|
|
|
|
| 链接本文: |
| http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1760.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2022/V11/I2/128 |
[1] 黄健. 中国泌尿外科前列腺癌诊断治疗指南更新要点解读(2019版)[J].中华泌尿外科杂志,2019,40(10):721-725.
[2] KUMAR J, JAZAYERI S B, GAUTAM S, et al.Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis[J]. Urol Oncol,2020,38(11):826-834.
[3] HEIDENREICH A, PFISTER D, MERSEBURGER A, et al.Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know[J]. Eur Urol,2013,64(2):260-265.
[4] 高旭,孙颖浩.非转移性去势抵抗性前列腺癌的治疗进展[J].中华泌尿外科杂志,2019,40(11):868-872.
[5] WHITE R, KHOR R, BRESSEL M, et al.Efficacy of high-dose palliative radiotherapy for localised, castration-resistant prostate cancer[J]. Clin Oncol (R Coll Radiol),2015,27(1):16-21.
[6] BOTTICELLA A, GUARNERI A, FILIPPI A R, et al.May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?[J]. J Cancer Res Clin Oncol,2013,139(11):1955-1960.
[7] SMITH M R, SAAD F, CHOWDHURY S, et al.Apalutamide treatment and metastasis-free survival in prostate cancer[J]. N Engl J Med,2018,378(15):1408-1418.
[8] HUSSAIN M, FIZAZI K, SAAD F, et al.Enzalutamide in men with nonmetastatic, Castration-Resistant prostate cancer[J]. N Engl J Med,2018,378(26):2465-2474.
[9] FIZAZI K, SHORE N, TAMMELA T L, et al.Darolutamide in nonmetastatic, Castration-Resistant prostate cancer[J]. N Engl J Med,2019,380(13):1235-1246.
[10] MORI K, MOSTAFAEI H, PRADERE B, et al.Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis[J]. Int J Clin Oncol,2020,25(11):1892-1900.
[11] SAAD F, SMALL E J, FENG F Y, et al.Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN[J]. Eur Urol,2022,81(2):184-192.
[12] SMALL EJ. Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies[C]. 2022 ASCO GU,2022: abstract 73. |
| [1] |
杜仁继, 缪惠东. 雄激素剥夺联合阿帕他胺治疗转移性激素敏感性前列腺癌2例报道[J]. 微创泌尿外科杂志, 2022, 11(2): 117-119. |
| [2] |
叶剑钧, 鲍一歌, 沈朋飞, 刘振华, 杨璐, 张朋, 李响, 曾浩, 魏强. 阿帕他胺治疗晚期前列腺癌32例报道[J]. 微创泌尿外科杂志, 2022, 11(2): 76-80. |
| [3] |
孙允冀, 张恒, 孙晓璐. 阿比特龙联合戈舍瑞林治疗前列腺根治性切除术后转移性去势抵抗前列腺癌患者的临床效果[J]. 微创泌尿外科杂志, 2022, 11(2): 91-94. |
| [4] |
胡恩平, 潘正波, 季广华, 师冠云. 1例前列腺癌患者随访10年报道及文献复习[J]. 微创泌尿外科杂志, 2022, 11(2): 112-116. |
| [5] |
张培新 贾宏亮 艾尼娃 蒲春林 陈建森 文彬 李鸣 李赟. 经会阴及经直肠前列腺穿刺活检安全性比较分析[J]. 微创泌尿外科杂志, 2016, 5(5): 281-284. |
| [6] |
成建军,柯鑫文,张华俊,程伟,尚吉文,米振国,张雁钢. 前列腺平滑肌肉瘤1例报告并文献复习[J]. 微创泌尿外科杂志, 2015, 4(1): 48-50. |
| [7] |
张帆, 黄毅, 陆敏, 马潞林. 临床低危型前列腺癌根治性切除术后病理升级的危险因素分析[J]. 微创泌尿外科杂志, 2013, 2(4): 280-283. |
|
|
|
|
